Ligand Pharmaceuticals Inc (LGND)
85.77
+0.48
(+0.56%)
USD |
NASDAQ |
May 15, 16:00
85.72
-0.04
(-0.05%)
Pre-Market: 20:00
Ligand Pharmaceuticals Free Cash Flow: -19.62M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
Date | Value |
---|---|
March 31, 2024 | -19.62M |
December 31, 2023 | -4.272M |
September 30, 2023 | 90.71M |
June 30, 2023 | 98.75M |
March 31, 2023 | 104.32M |
December 31, 2022 | 119.93M |
September 30, 2022 | 93.07M |
June 30, 2022 | 96.13M |
March 31, 2022 | 109.82M |
December 31, 2021 | 70.04M |
September 30, 2021 | 43.50M |
June 30, 2021 | 35.95M |
March 31, 2021 | 40.56M |
December 31, 2020 | 50.13M |
September 30, 2020 | 43.88M |
June 30, 2020 | 26.98M |
March 31, 2020 | -57.67M |
December 31, 2019 | -29.34M |
September 30, 2019 | 10.58M |
June 30, 2019 | 43.85M |
March 31, 2019 | 178.56M |
December 31, 2018 | 194.06M |
September 30, 2018 | 192.80M |
June 30, 2018 | 193.36M |
March 31, 2018 | 130.11M |
Date | Value |
---|---|
December 31, 2017 | 88.57M |
September 30, 2017 | 82.97M |
June 30, 2017 | 71.66M |
March 31, 2017 | 52.98M |
December 31, 2016 | 41.19M |
September 30, 2016 | 27.28M |
June 30, 2016 | 20.10M |
March 31, 2016 | 33.97M |
December 31, 2015 | 30.86M |
September 30, 2015 | 26.75M |
June 30, 2015 | 21.06M |
March 31, 2015 | 19.44M |
December 31, 2014 | 16.07M |
September 30, 2014 | 19.42M |
June 30, 2014 | 15.38M |
March 31, 2014 | 14.66M |
December 31, 2013 | 15.75M |
September 30, 2013 | 6.932M |
June 30, 2013 | 2.714M |
March 31, 2013 | -1.505M |
December 31, 2012 | -8.483M |
September 30, 2012 | -6.513M |
June 30, 2012 | -2.897M |
March 31, 2012 | -9.968M |
December 31, 2011 | -4.125M |
Free Cash Flow Range, Past 5 Years
-57.67M
Minimum
Mar 2020
119.93M
Maximum
Dec 2022
48.36M
Average
43.87M
Median
Free Cash Flow Benchmarks
ANI Pharmaceuticals Inc | 95.06M |
Annovis Bio Inc | -35.37M |
ADMA Biologics Inc | 15.91M |
United Therapeutics Corp | 752.40M |
Blueprint Medicines Corp | -429.98M |
Free Cash Flow Related Metrics
Cash from Operations (Quarterly) | 18.73M |
Cash from Investing (Quarterly) | -3.775M |
Cash from Financing (Quarterly) | 12.18M |
Free Cash Flow Per Share (Quarterly) | 0.8931 |
Free Cash Flow to Equity (Quarterly) | 16.18M |
Free Cash Flow to Firm (Quarterly) | 16.18M |
Free Cash Flow Yield | -1.29% |